Merlin Test reduces unnecessary surgeries and associated complications for melanoma patients
Excerpt from the Press Release:
ROTTERDAM, Netherlands and SAN DIEGO, Feb. 24, 2022 /PRNewswire/ — Today, SkylineDx announced that their Merlin Test for melanoma patients would have been able to reduce over 59% of surgery-related complications by means of deselecting patients for surgery [2]. The commercially available Merlin Test identifies melanoma patients that can safely forgo a sentinel lymph node biopsy (SLNB) surgery, a procedure used to determine metastatic spread of the cancer for staging purposes. In approximately 80% of patients the biopsy comes back negative for metastasis and could therefore have been avoided [3]. Merlin addresses an important clinical unmet need by identifying these patients with a low risk of metastasis at diagnosis and can therefore not only reduce unnecessary surgeries but also associated complications. Results have been published in a peer-reviewed and scientific journal, the International Journal of Dermatology [2].
The authors investigated the rate of complications associated with the SLNB procedure. For a total of 558 patients, electronic medical records were analyzed to determine surgery related complications. Their data shows that SLNB-related complications are relatively common as 17.4% developed at least one complication. The most common complications were seroma (9.3%), infection/cellulitis (4.8%) and lymphedema (4.3%). Moreover, six patients (1.1%) sought help in a hospital’s emergency department within 30 days of surgery and nine patients (1.6%) were readmitted to the hospital within 30 days of surgery. Of the 558 patients, 279 (51%) had a Merlin Test Low-Risk result. Omission of SLNB surgery in these 279 patients would have decreased complications by 59.2%, in this cohort. [2]
About Merlin Test
The Merlin Test uses the CP-GEP model, a powerful algorithm that calculates the risk of metastasis in a patient’s sentinel lymph nodes [3]. The model is able to calculate risk on an individual basis through a combination analysis of 8 genes from the patient’s primary tumor, the tumor thickness and the patient’s age; and has been independently validated in several cohorts.
Click the button below to read the entire Press Release:
Discover What Sets TrialStat Apart From Ordinary EDC Platforms
Click the image or button below to explore our eClinical Suite Platform and discover what sets TrialStat apart from competing EDC platforms.
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?